Canaccord raises iRhythm stock price target on strong margins

iRhythm reported Q3 revenue of $221.6 million, up 14.9% year over year and roughly in line with estimates, while adjusted EBITDA was $51.2 million at a 23.1% margin, above the company’s 12%–13% guidance. Canaccord raised its price target to $206 from $196 and maintained a Buy rating; management also raised fiscal 2026 guidance and expects about $1 billion of organic revenue with at least a 15% adjusted EBITDA margin in 2027. Risks include flat Zio AT revenue, a Zio MCT FDA submission pushed to 2027, and near-term VitalConnect integration complexity; the article says these concerns may have contributed to a stock decline but gives no magnitude.

Analysis

The key signal is the divergence between nearly plan-level revenue and a very large adjusted EBITDA beat. If repeatable, this suggests meaningful operating leverage; if driven by timing, acquisition accounting, or adjustments, the market may be capitalizing an unusually strong quarter into a durability premium. Verify the EBITDA bridge, cash conversion, and whether VitalConnect adds revenue without obscuring organic growth before treating the margin as a new run rate.

Near term, integration and onboarding are the bottleneck, not demand proof: deferred Zio AT accounts leave room for competing cardiac-monitoring providers to capture clinician workflow and installed-base share. The Zio MCT filing delay extends the period in which iRhythm lacks that product catalyst; slippage again would weaken the 2027 growth narrative. Conversely, successful VitalPatch integration and resumed account activation could convert the currently deferred pipeline into growth, but timing is not yet evidence of conversion.

Over 1–3 months, focus on organic revenue, Zio AT account activations, and EBITDA-to-cash reconciliation rather than the raised consolidated outlook, which includes VitalConnect. Over 6–18 months, execution on integration and the MCT regulatory path will determine whether the margin beat supports durable earnings power. Contrarian read: the beat may be more informative than the modest revenue miss, but one quarter is insufficient to establish a higher margin floor. The bullish thesis is falsified by continued flat Zio AT revenue, another MCT delay, or a material reversal in adjusted margins/cash generation.

Key Decisions for Investors

• Do not chase IRTC solely on the EBITDA surprise or analyst target increase. Keep exposure neutral pending the next report’s organic growth and cash-conversion detail; treat the headline margin as provisional until reconciled.
• Set a 1–3 month catalyst watch on Zio AT onboarding and VitalPatch integration. Upgrade the view only if deferred accounts begin activating and organic growth—not just acquired revenue—improves.
• For existing long exposure, consider a defined-risk collar or reduce position size if the stock rallies before those operating signals appear; the principal downside is multiple compression if the margin beat proves non-recurring.
• Reassess promptly if management delays the Zio MCT submission again, Zio AT remains flat, or adjusted EBITDA margins materially retreat. These would undermine the 2027 profitability and growth case.